|
��չ����
|
|
| ������Ϣ | |
 |
Supporting info |
|
PDFȫ�� |
|
[HTMLȫ��] |
|
����� |
| �����뷴�� | |
|
�������ù����� |
|
���� |
|
Email Alert |
|
���·��� |
|
���������Ϣ |
| ���Ĺؼ���������� | |
|
�������� |
|
Ƥ������ |
| ��������������� | |
|
���� |
|
����� |
| PubMed | |
|
Article by |
|
Article by |
��Դ������LL-37��Ƥ����
����, �����
���пƼ���ѧͬ��ҽѧԺ����Э��ҽԺƤ����, �人 430022
LL-37��һ�ֽ������������ڷ��ֵ�����cathelicidins����Ŀ�����.����������,�������а��װ���,�����ڶ����,Ϊ���Ц������ṹ�����Է���.�����й��Ŀ�������,�������������з�������Ҫ������,���㷺������������һЩ��֢�Լ����ķ�����չ����.���о�����ӽṹ�������ء�����ѧ���ܼ�����Ƥ����������о���չ��һ����.
[2] Bals R. Epithelial antimicrobial peptides in host defense against infection. Respir Res, 2000, 1(3):141-150.
[3] Larrick JW, Hirata M, Balint RF, et al. Human CAP18:a novel antimicrobial lipopolysaccharide-binding protein. Infect Immun, 1995,63(4):1291-1297.
[4] Cowland JB, Johnsen AH, Borregaard N. hCAP-18, a cathelin/probactenecin-like protein of human neutrophil specific granules. FEBS Lett, 1995, 368(1):173-176.
[5] Sorensen OE, Follin P, Johnsen AH, et al. Human cathelicidin,hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood, 2001,97(12):3951-3959.
[6] Johansson J, Gudmundsson GH, Rottenberg ME, et al. Conformationdependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem, 1998, 273(6):3718-3724.
[7] Sorensen O, Bratt T, Johnsen AH, et al. The human antibacterial cathelicidin, hCAP18, is bound to lipoproteins in plasma. J Biol Chem, 1999,274(32):22445-22451.
[8] Gudmundsson GH, Agerberth B, Odeberg J, et al. The human gene FALL39 and processing of the cathelin precursor to the antibacterial peptide LL-37 in granulocytes. Eur J Biochem, 1996,238(2):325332.
[9] Bals R, Wang X, Zasloff M, et al. The peptide antibiotic LL-37/hCAP-18 is expressed in epithelia of the human lung where it has broad antimicrobial activity at the airway surface. Proc Natl Acad Sci U S A, 1998, 95(16):9541-9546.
[10] Nagaoka I, Hirota S, Yomogida S, et al. Synergistic actions of antibacterial neutrophil defensins and cathelicidins. Inflamm Res, 2000,49(2):73-79.
[11] Kirikae T, Hirata M, Yamasu H, et al. Protective effects of a human 18kilodalton cationic antimicrobial protein(CAP18)-derived peptide against murine endotoxemia. Infect Immun, 1998, 66(5):18611868.
[12] De Yang, Chen Q, Schmidt AP, et al. LL-37, the neutrophil granuleand epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1(FPRL1)as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J Exp Med, 2000, 192(7):1069-1074.
[13] Scott MG, Davidson DJ, Gold MR, et al. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J Immunol, 2002, 169(7):3883-3891.
[14] Niyonsaba F, Someya A, Hirata M, et al. Evaluation of the effects of peptide antibiotics human beta-defensins 1/2 and LL-37 on histamine release and prostaglandin D(2)production from mast cells.Eur J Immunol, 2001,31(4):1066-1075.
[15] Niyonsaba F, lwabuchi K, Someya A, et al. A cathelicidin family of human antibacterial peptide LL37 induces mast cell chemotaxis.Immunology, 2002, 106(1):20-26.
[16] Zaiou M, Nizet V, Gallo RL. Antimicrobial and protease inhibitory functions of the human cathelicidin(hCAP18/LL37)prosequence.J Invest Dermatol, 2003, 120(5):810-816.
[17] Turner J, Cho Y, Dinh NN, et al. Activities of LL37, a cathelinassociated antimicrobial peptide of human neutrophils. Antimicrob Agents Chemother, 1998, 42(9):2206-2214.
[18] Frohm M, Agerberth B, Ahangari G, et al. The expression of the gene coding for the antibacterial peptide LL-37 is induced in human keratinocytes during inflammatory disorders. J Biol Chem, 1997, 272(24):15258-15263.
[19] Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med, 2002,347(15):1151-1160.
[20] Conner K, Nern K, Rudisill J, et al. The antimicrobial peptide LL-37 is expressed by keratinocytes in condyloma acuminatum and yerruca vulgaris. J Am Acad Dermatol, 2002, 47(3):347-350.
[21] Sambri V, Marangoni A, Giacani L, et al. Comparative in vitro activity of five cathelicidin-derived synthetic peptides against Leptospira,Borrelia and Treponema pallidum. J Antimicrob Chemother, 2002, 50(6):895-902
[22] Shafer WM, Qu X, Waring AJ, et al. Modulation of Neisseria gonorrhoeae susceptibility to vertebrate antibacterial peptides due to a member of the resistance/nodulation/division efflux pump family. Proc Natl Acad Sci U S A, 1998, 95(4):1829-1833.
[23] Marchini G, Lindow S, Brismar H, et al. The newborn infant is protected by an innate antimicrobial barrier:peptide antibiotics are present in the skin and vernix cazeosa. Br J Dermatol, 2002, 147(6):1127-1134.
[24] Heilborn JD, Nilsson MF, Kratz G, et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of humanskin wounds and is lacking in chronic ulcer epithelium. J Invest Dermatol, 2003, 120(3):379-389.
[25] Lusitani D, Malawista SE, Montgomery RR. Borrelia burgdorferi are susceptible to killing by a variety of human polymorpbonuclear leukocyte components. J Infect Dis, 2002, 185(6):797-804.